← Back to Clinical Trials
Recruiting NCT03832062

NCT03832062 Value of Analysing Under-utilised Leftover Tissue (VauLT)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT03832062
Status Recruiting
Phase
Sponsor Royal Marsden NHS Foundation Trust
Condition Oncology
Study Type OBSERVATIONAL
Enrollment 800 participants
Start Date 2018-09-10
Primary Completion 2028-08-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Leftover surgical tissue homogenization

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 800 participants in total. It began in 2018-09-10 with a primary completion date of 2028-08-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Intratumour heterogeneity is well recognized in multiple cancer types and ultimately leads to therapeutic resistance. It also limits the ability of small samples to represent the whole tumour, having implications for diagnosis, molecular analysis and understanding of the tumour immune microenvironment. By blending- 'homogenizing'- leftover tumour tissue in excess of that required for diagnosistic purposes, one may create a more representative sample for analysis.

Eligibility Criteria

Inclusion Criteria: 1. Leftover formalin-fixed tissue (ie that would be otherwise discarded by histopathology) from cancer surgery. 2. Tissues for Research consent has been provided. 3. Patient age \>18yo. 4. Minimum of 1 gram of residual tumour remaining in leftover surgical tissue 5. Minimum of 1 gram of normal tissue present. Exclusion Criteria: 1. Advanced Practitioner in histological dissection deems tumour sample to be inadequate. 2. Leftover surgical tumour tissue greater than 20kg.

Contact & Investigator

Central Contact

Serena Vanzan

✉ vault@rmh.nhs.uk

📞 020 3186 5161

Principal Investigator

Samra Turajlic

STUDY CHAIR

Royal Marsden NHS Foundation Trust

Frequently Asked Questions

Who can join the NCT03832062 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Oncology. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT03832062 currently recruiting?

Yes, NCT03832062 is actively recruiting participants. Contact the research team at vault@rmh.nhs.uk for enrollment information.

Where is the NCT03832062 trial being conducted?

This trial is being conducted at London, United Kingdom.

Who is sponsoring the NCT03832062 clinical trial?

NCT03832062 is sponsored by Royal Marsden NHS Foundation Trust. The principal investigator is Samra Turajlic at Royal Marsden NHS Foundation Trust. The trial plans to enroll 800 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology